Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-mAbs Therapeutics, Inc. Announces Executive Changes

11/24/2021 | 04:04pm EST

On November 22, 2021, Mr. Phillip Herman notified Y-mAbs Therapeutics Inc., (of his resignation as the Company?s SVP, Chief Commercial Officer, to be effective as of December 31, 2021. The Company has initiated a process to select a successor to Mr. Herman. The Company?s Chief Executive Officer, Dr. Claus M?ller, will assume the role of interim Chief Commercial Officer of the Company beginning with Mr. Herman?s last working day and continuing until such time as a new Chief Commercial Officer commences employment with the Company.


ę S&P Capital IQ 2021
All news about Y-MABS THERAPEUTICS, INC.
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Pipeline Update
AQ
2021INSIDER SELL : Y-mAbs Therapeutics
MT
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 66,7 M - -
Net income 2021 -49,0 M - -
Net cash 2021 85,0 M - -
P/E ratio 2021 -11,0x
Yield 2021 -
Capitalization 529 M 529 M -
EV / Sales 2021 6,66x
EV / Sales 2022 1,80x
Nbr of Employees 125
Free-Float -
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 12,12 $
Average target price 43,40 $
Spread / Average Target 258%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Director, Chief Executive & Commercial Officer
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-25.23%529
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 665
BIONTECH SE-23.97%47 338